ANI Pharmaceuticals, Inc. is a diversified biopharmaceutical company engaged in developing, manufacturing, and commercializing therapeutics. Its Rare Disease and Brands segment consists of two reporting units. The Rare Disease unit consists of operations related to the development, manufacturing, and marketing of branded pharmaceutical products, with a focus on products used in the treatment of patients with rare disease conditions and consists of operations related to Cortrophin Gel, ILUVIEN and YUTIQ. In addition, the Brands reporting unit includes a portfolio of over 16 brand products that are principally sold in genericized markets. Its Generics and Other segment consist of operations related to the development, manufacturing, and marketing of generic pharmaceutical products, including those sold through traditional wholesale and retail sales channels, sales of contract manufactured products, royalties on contract manufactured products, product development services, and others.
High Growth
The company's revenue has grown steadily over the past 3 years, averaging 81.46% year-on-year.
High Profit Growth
The company's net income leads the industry, with the latest annual income totaling USD 883.37M.
Turnaround to Profit
The company's performance has turned profitable, with the latest annual net income of USD .
Fairly Valued
The company’s latest PE is 20.19, at a medium 3-year percentile range.
Institutional Buying
The latest institutional holdings are 23.15M shares, increasing 0.25% quarter-over-quarter.
Held by John Hussman
Star Investor John Hussman holds 49.41K shares of this stock.